Characterization of metalloproteinases, oxidative status and inflammation levels in the different stages of fibrosis in HCV patients

Clinical Biochemistry

Volumn 45, Issue 7-8, 2012, Pages 525-529

  Capone, F ^a   Guerriero, E ^a   Sorice, A ^a   Maio, P ^b   Colonna, G ^c   Castello, G ^a   Costantini, S ^a  

^a CROM   (Italy)

^b Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cytokines; Fibrosis; HCV; Marker; MMPs; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; FERRIC ION; FERROUS ION; GELATINASE B; HYDROPEROXIDE; MATRILYSIN; NERVE GROWTH FACTOR BETA SUBUNIT; NEUTROPHIL COLLAGENASE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; AUTOANALYZER; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLAMMATION; LABORATORY DEVICE; LIVER FIBROSIS; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY;

ANTIOXIDANTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NERVE GROWTH FACTOR; NITRIC OXIDE; OXIDATIVE STRESS; SENSITIVITY AND SPECIFICITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84860144758     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.02.004     Document Type: Article

References (35)

1. Costantini S., Capone F., Guerriero E., Maio P., Colonna G., Castello G. Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis. Eur Cytokine Netw 2010, 21:251-256.
2. Gross J., Lapiere C. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A 1962, 48:1014-1022.
3. Badra G., Lotfy M., El-Refaie A., Obada M., Abdelmonem E., Kandeel S., et al. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. Acta Microbiol Immunol Hung 2010, 57:29-42.
4. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodeling. Nat Rev Mol Cell Biol 2007, 8:221-233.
5. Parks W.C., Wilson C.L., Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004, 4:617-629.
6. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
7. Canbay A., Feldstein A.E., Higuchi H., Werneburg N., Grambihler A., Bronk S.F., et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003, 38:1188-1198.
8. Bruno C.M., Valenti M., Bertino G., Ardiri A., Consolo M., Mazzarino C.M., et al. Altered pattern of circulating matrix metalloproteinases-2, -9 and tissue inhibitor of metalloproteinase-2 in patients with HCV-related chronic hepatitis. Relationship to histological features. Panminerva Med 2009, 51:191-196.
9. Sies H. Oxidative stress: introductory remarks 1985, Academic Press, London.
10. Parola M., Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001, 35:297-306.
11. Diesen D.L., Kuo P.C. Nitric oxide and redox regulation in the liver. Part I: general considerations and redox biology in hepatitis. J Surg Res 2010, 162:95-109.
12. Afdhal N.H., Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004, 99:1160-1174.
13. Asselah T., Bièche I., Laurendeau I., Paradis V., Vidaud D., Degott C., et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005, 129:2064-2075.
14. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
15. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
16. Cesarone M.R., Belcaro G., Caratelli M., Cornelli U., De Sanctis M.T., Incandela L., et al. A simple test to monitor oxidative stress. Int Angiol 1999, 18:127-130.
17. Cornelli U., Terranova R., Luca S., Cornelli M., Alberti A. Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr 2001, 131:3208-3211.
18. Iriz F., Benzie F., Strain J.J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996, 239:70-76.
19. Capone F., Costantini S., Guerriero E., Calemma R., Napolitano M., Scala S., et al. Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw 2010, 21:99-104.
20. Jung K. Matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in Blood. Arterioscler Thromb Vasc Biol 2008, 28:e15-e16.
21. Kang H.S., Kim J.H., Phi J.H., Kim Y.Y., Kim J.E., Wang K.C., et al. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry 2010, 81(6):673-678.
22. Marcellin P., Asselah T., Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002, 36:S47-S56.
23. Clichici S., Catoi C., Mocan T., Filip A., Login C., Nagy A., et al. Non-invasive oxidative stress markers for liver fibrosis development in the evolution of toxic hepatitis. Acta Physiol Hung 2011, 98:195-204.
24. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494.
25. Patil D.P., Kundu G.C. MMP9 (matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)). Atlas Genet Cytogenet Oncol Haematol 2006, 3:356-362.
26. Helaly G.F. Differences in circulating MMP-9 levels with regard to viral load and AST:ALT ratio between chronic hepatitis B and C patients. Br J Biomed Sci 2011, 68:38-42.
27. Avolio C., Filippi M., Tortorella C., Rocca M.A., Ruggieri M., Agosta F., et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler 2005, 11(4):441-446.
28. Abdel-Moneim S.S., Abdou Mostafa E.F., Osama A. Circulating matrix metalloproteinase-1 (MMP-1) and tissue inhibitor metalloproteinase-1 (TIMP-1) as serum markers of liver fibrosis in patients with chronic viral hepatitis. Arab J Gastroenterol 2008, 9:39-43.
29. Elsharkawy A.M., Oakley F., Mann D.A. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005, 10:927-939.
30. Rasi G., Serafino A., Bellis L., Lonardo M.T., Andreola F., Zonfrillo M., et al. Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2007, 13:4986-4995.
31. Lee M.W., Park S.C., Kim J.-H., Han K.S., Kim K.Y., Lee W.B., et al. The involvement of oxidative stress in tumor necrosis factor (TNFα)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in HeLa cells. Cancer Lett 2002, 182:75-82.
32. Mundt B., Wirth T., Zender L., Waltemathe M., Trautwein C., Manns M.P., et al. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 2005, 54:1590-1596.
33. Pilipović K., Župan Ž., Dangubić B., Mršić-Pelčić J., Župan G. Oxidative stress parameters in different brain structures following lateral fluid percussion injury in the rat. Neurochem Res 2011, 36:913-921.
34. Martinez S.M., Crespo G., Navasa M., Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011, 53:325-335.
35. Castera L., Sebastiani G., Le Bail B., de Ledinghen V., Couzigou P., Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010, 52:191-198.